Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 36

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Biomedical Applications of a Novel Class of High-Affinity Peptides

Saw, Phei Er, Xu, Xiaoding, Kim, Sunghyun, Jon, Sangyong · 2021 · Accounts of Chemical Research

Abstract

Conspectus Most therapeutic peptides available on the market today are naturally occurring hormones or protein fragments that were serendipitously discovered to possess therapeutic effects. However, the limited repertoire of available natural resources presents difficulties for the development of new peptide drug candidates. Traditional peptides possess several shortcomings that must be addressed for biomedical applications, including relatively low affinity or specificity toward biological targets compared to antibody- and protein scaffold-based affinity molecules, poor in vivo stability owing to rapid enzymatic degradation, and rapid clearance from circulation owing to their small size. Going forward, it will be increasingly important for scientists to develop novel classes of high-affinity and -specificity peptides against desired targets that mitigate these limitations while remaining compatible with pharmaceutical manufacturing processes. Recently, several highly constrained, artificial cyclic peptides have emerged as platforms capable of generating high-affinity peptide binders against various disease-associated protein targets by combining with phage or mRNA display method, some of which have entered clinical trials. In contrast, although linear peptides are relatively easy to synthesize cost-effectively and modify site-specifically at either N- or C-termini compared to cyclic peptides, there have been few linear peptide-based platforms that can provide high-affinity and -specificity peptide binders. In this Account, we describe the creation and development of a novel class of high-affinity peptides, termed “aptide”—from the Latin word “ apt us ” meaning “to fit” and “pep tide ”—and summarize their biomedical applications. In the first part, we consider the design and creation of aptides, with a focus on their unique structural features and binding mode, and address screening and identification of target protein-specific aptides. We also discuss advantages of the aptide platform over ordinary linear peptides lacking preorganized structures in terms of the affinity and specificity of identified peptide binders against target molecules. In the second part, we describe the potential biomedical applications of various target-specific aptides, ranging from imaging and therapy to theranostics, according to the types of aptides and diseases. We show that certain aptides can not only bind to a target protein but also inhibit its biological function, thereby showing potential as therapeutics per se . Further, aptides specific for cancer-associated protein antigens can be used as escort molecules or targeting ligands for delivery of chemotherapeutics, cytokine proteins, and nanomedicines, such as liposomes and magnetic particles, to tumors, thereby substantially improving therapeutic effects. Finally, we present a strategy capable of overcoming the critical issue of short blood circulation time associated with most peptides by constructing a hybrid system between an aptide and a hapten cotinine-specific antibody.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.accounts.1c00239

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 77

  1. 10.1002/anie.201107894 · DOI
  2. 10.1158/0008-5472.CAN-13-2187 · doi:10.1158/0008-5472.can-13-2187
  3. 10.1002/anie.201811509 · doi:10.1002/anie.201811509
  4. 10.1038/417584a · DOI
  5. 10.1057/jcb.2010.37 · doi:10.1057/jcb.2010.37
  6. DePalma A., 2015, Genetic Engineering & Biotechnology News, 35, 24, 10.1089/gen.35.09.13 · doi:10.1089/gen.35.09.13
  7. 10.3390/ijms20246289 · DOI
  8. 10.1016/j.drudis.2009.10.009 · DOI · Paper page
  9. 10.1016/j.coph.2008.06.002 · DOI · Paper page
  10. 10.1002/jcph.407 · DOI
  11. 10.1016/j.canlet.2021.03.015 · DOI
  12. 10.1126/sciadv.aay2174 · DOI
  13. 10.1073/pnas.2024102118 · DOI
  14. 10.1038/s41573-020-00135-8 · DOI · Paper page
  15. 10.1038/s41570-019-0159-2 · DOI · Paper page
  16. 10.1016/j.cbpa.2017.02.006 · DOI · Paper page
  17. 10.1016/S0169-409X(02)00179-5 · DOI · Paper page
  18. 10.1021/acs.accounts.7b00184 · DOI · Paper page
  19. 10.1002/chem.201300247 · DOI
  20. 10.1007/s13238-019-0639-7 · DOI · Paper page
  21. 10.1038/nmeth877 · DOI · Paper page
  22. 10.1038/nchembio.184 · DOI · Paper page
  23. 10.4062/biomolther.2019.082 · DOI
  24. 10.15212/bioi-2020-0033 · doi:10.15212/bioi-2020-0033
  25. 10.1016/S0092-8674(05)80070-4 · DOI · Paper page
  26. 10.1073/pnas.091100898 · DOI · Paper page
  27. 10.1021/cr960065d · DOI · Paper page
  28. 10.1007/s12033-019-00156-8 · DOI
  29. 10.1126/science.4001944 · DOI · Paper page
  30. 10.1088/0957-4484/27/48/48LT01 · DOI
  31. 10.1021/acs.molpharmaceut.7b00520 · DOI
  32. 10.1002/adhm.201500190 · DOI
  33. 10.1016/j.biomaterials.2013.12.031 · DOI
  34. 10.1016/j.jconrel.2017.04.036 · doi:10.1016/j.jconrel.2017.04.036
  35. 10.1039/c3tb20613k · DOI
  36. 10.1016/j.jconrel.2014.07.006 · DOI
  37. 10.1039/C6MD00696E · doi:10.1039/c6md00696e
  38. 10.1002/cbic.201402450 · doi:10.1002/cbic.201402450
  39. 10.1002/anie.201404750 · DOI
  40. 10.1056/NEJM199412013312203 · DOI · Paper page
  41. 10.1038/nm0603-669 · DOI · Paper page
  42. Miller J. W., 1994, Am. J. Pathol., 145, 574
  43. 10.1074/jbc.273.32.20556 · DOI · Paper page
  44. 10.1016/j.ophtha.2005.02.007 · DOI · Paper page
  45. 10.1006/jmbi.1999.3192 · DOI · Paper page
  46. 10.1038/nrc2734 · DOI · Paper page
  47. 10.1038/nri1995 · DOI · Paper page
  48. 10.3390/molecules24050927 · DOI · Paper page
  49. 10.3389/fphar.2020.00697 · DOI · Paper page
  50. 10.1016/j.ejphar.2020.173107 · DOI
  51. 10.1084/jem.20191761 · DOI
  52. 10.1021/acsnano.8b02330 · DOI
  53. 10.1016/j.jconrel.2021.02.022 · DOI
  54. 10.1002/ijc.2910590507 · DOI · Paper page
  55. 10.1002/ijc.21677 · DOI · Paper page
  56. 10.1016/j.pharmthera.2016.07.012 · DOI
  57. 10.1158/1541-7786.MCR-19-0582 · DOI · Paper page
  58. 10.1039/D0CS00556H · DOI · Paper page
  59. 10.1039/c3tb20815j · DOI
  60. 10.1016/j.jconrel.2014.01.015 · DOI
  61. 10.1172/JCI65624 · DOI
  62. 10.1038/ncponc0426 · DOI
  63. 10.1038/bjc.1996.652 · DOI
  64. 10.1146/annurev-bioeng-071812-152409 · DOI · Paper page
  65. 10.1039/C2CS15261D · DOI · Paper page
  66. 10.2147/IJN.S53717 · DOI · Paper page
  67. 10.1038/nature06917 · DOI · Paper page
  68. 10.1021/ar200019c · DOI · Paper page
  69. 10.2217/17435889.3.2.137 · DOI · Paper page
  70. 10.7150/thno.44948 · DOI
  71. 10.7150/thno.8343 · DOI
  72. 10.1007/s40262-013-0079-0 · DOI · Paper page
  73. 10.4161/mabs.21024 · DOI
  74. Bhat A., 2013, Fusion Protein Technologies for Biopharmaceuticals, 571, 10.1002/9781118354599.ch38 · doi:10.1002/9781118354599.ch38
  75. 10.1016/j.ccr.2004.09.030 · DOI · Paper page
  76. 10.1021/acs.molpharmaceut.8b00924 · doi:10.1021/acs.molpharmaceut.8b00924
  77. 10.3858/emm.2012.44.9.063 · doi:10.3858/emm.2012.44.9.063

Cited by

See all 36

Metadata

Authors
Saw, P. E., Xu, X., Kim, S., & Jon, S.
Affiliations
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang West Road, Guangzhou 510120, P.R. China
  • Center for Convergence Bioceramic Materials, Korea Institute of Ceramic Engineering and Technology (KICET), Cheongju-si 28160, Republic of Korea
  • Center for Precision Bio-Nanomedicine, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon 34141, South Korea
Venue
Accounts of Chemical Research
Published
2021-08-18
Volume
54
Issue
18
Pages
3576-3592
ISSN
  • 0001-4842
  • 1520-4898
Cited by
36
References
3
Language
en
Funders
  • National Research Foundation of Korea (NRF-2018R1A3B1052661, NRF-2020R1F1A1064124)
  • National Natural Science Foundation of China (81803020, 82072930)
  • Guangdong Province (2021B1515020066)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.